Can You Use Ozempic and Mounjaro at the Same Time?

What the pharmacology tells us about combining semaglutide and tirzepatide

Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which activates both the GLP-1 receptor and the GIP receptor, making it the only dual-agonist weight-loss medicine licensed in the UK. Because tirzepatide already fully occupies the GLP-1 receptor pathway, adding semaglutide on top would not open a new therapeutic route. You would simply be delivering two competing signals to the same receptor simultaneously.

The consequences matter. GLP-1 agonism is strongly associated with gastrointestinal side effects, nausea, vomiting, diarrhoea, slowed gastric emptying. Those effects are dose-related. Layering two medicines that both drive them creates a meaningful risk of compounded harm: severe dehydration, acute kidney injury from GI fluid losses, and a significantly raised risk of pancreatitis. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines already flags acute pancreatitis as an infrequent but serious concern with these medicines individually; the risk profile of combining them has not been studied in clinical trials because no ethical review board would approve such a design.

There is a related question our prescribers hear occasionally: whether taking the two in the same week rather than on the same day changes the calculation. It does not. The issue is not timing within a week, it is concurrent therapy full stop. If you are wondering whether Wegovy and Mounjaro can be taken at the same time, the answer follows the same reasoning, as combining any two GLP-1 pathway medicines carries the same compounded risks.

Ozempic's UK licence does not cover weight loss, so the question partly answers itself

Before the pharmacology even becomes relevant, there is a licensing reality. In the UK, Ozempic is authorised by the MHRA for type 2 diabetes management, not for weight management. Wegovy (also semaglutide, but at a higher 2.4mg maintenance dose (and now available up to 7.2mg)) holds the weight-management licence. Ozempic and tirzepatide are different medicines serving different licensed purposes. A prescriber cannot lawfully issue Ozempic for weight loss as a primary indication under normal circumstances, which means the combination you are asking about is doubly blocked: once by safety, once by licensing.

The NHS weight-management injections guidance published by NHS England makes this distinction clearly. It lists Wegovy (semaglutide) and Mounjaro (tirzepatide) as the medicines within scope for weight management; Ozempic does not appear in that context. If your GP has prescribed Ozempic for diabetes and you are separately exploring weight-loss treatment, those two conversations need to happen together, your diabetes prescriber must be involved in any decision about adding a second agent.

For a fuller picture of how the two licensed-for-weight-loss options compare with each other, the Wegovy versus Mounjaro comparison covers the trial evidence in detail.

What the clinical trials actually show for each medicine on its own

The evidence base for each medicine, used alone and as licensed, is substantial. In the SURMOUNT-1 trial (2,539 adults without diabetes, 72 weeks), tirzepatide at the 15mg maintenance dose produced an average body-weight reduction of around 20–21%, as published in the New England Journal of Medicine. In the STEP 1 trial (68 weeks), semaglutide 2.4mg produced an average reduction of around 15%. The SURMOUNT-5 head-to-head trial (72 weeks, published in the NEJM in 2025) compared the two directly and found tirzepatide produced greater average weight reduction than semaglutide 2.4mg. The gap narrows at the newer 7.2mg semaglutide dose.

These figures are from trials where participants used one medicine, not two. There is no equivalent dataset for a combination. The honest clinical summary is that neither medicine needs a partner to achieve meaningful results in the right patient, and that trying to stack them does not replicate the dual-agonist design of tirzepatide, it just doubles the receptor load without a coherent rationale.

What to do if you are already on Ozempic for diabetes and want to discuss weight management

This is a genuinely common clinical situation and a reasonable one to raise. If you use Ozempic for blood-glucose control and your weight is also a concern, the answer is not to add a second injection. The conversation to have is with your diabetes prescriber about whether your current regimen could be reviewed, or whether a medicine with a dual licence (covering both diabetes and weight management, as tirzepatide does) might better serve both goals in one prescription.

If you are not currently on any GLP-1 medicine and are starting fresh, a free consultation with our prescribers covers your full history, current medicines and BMI to identify which licensed treatment, if any, is appropriate for you. A real clinician reads your answers the same day. The medicines are stored in the fridge (one pen every four weeks for Mounjaro) and arrive the next working day via DPD in plain packaging once approved. You can read more about how semaglutide and tirzepatide compare as drug classes, or explore our treatment overview to understand your options before consulting. Which medicine suits your situation is a clinical decision our prescribers make with you.